| Indicators | Browse All

Seaport Therapeutics, Inc. (SPTX)

Healthcare | Biotechnology | Boston, United States | NasdaqGS
24.04 USD -2.21 (-8.419%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 24.04

Short-term:★★★⯪☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 3:04 a.m. EDT

The immediate outlook is driven by a powerful post-IPO momentum surge. Following a significant 17% price jump on its Nasdaq debut and an upsized IPO that raised $255 million, the stock has rallied approximately 16% over the last two months, trading well above its 50-day moving average. This technical strength suggests a high-conviction entry is developing for the near term as the market digests the fresh capital and initial sentiment. However, the long-term picture remains fundamentally opaque due to the lack of historical price data; without a multi-year track record to assess business quality or valuation stability, the investment thesis relies entirely on future clinical results rather than proven performance. Furthermore, the company is a pure-play biotech with negative earnings and no dividend history, making it unsuitable for income investors and exposing shareholders to significant volatility until the next major catalyst.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.061570
AutoETS0.095296
MSTL0.097667
AutoARIMA0.122093

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 41%
H-stat 0.72
Ljung-Box p 0.000
Jarque-Bera p 0.604
Excess Kurtosis -0.73
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.187
Market Cap 1,286,874,496
Forward P/E -9.34
Website https://www.seaporttx.com

Info Dump

Attribute Value
52 Week Change 0.21169353
Address1 101 Seaport Blvd.
Address2 Floor 12
All Time High 28.38
All Time Low 14.85
Ask 31.61
Ask Size 2
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 123,490
Average Daily Volume3 Month 161,936
Average Volume 161,936
Average Volume10Days 123,490
Bid 18.62
Bid Size 2
Book Value -44.549
City Boston
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 24.04
Current Ratio 18.003
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 26.865
Day Low 24.04
Debt To Equity 1.187
Display Name Seaport Therapeutics
Ebitda -143,751,008
Ebitda Margins 0.0
Enterprise To Ebitda -7.086
Enterprise Value 1,018,581,440
Eps Current Year -5.90027
Eps Forward -2.57328
Eps Trailing Twelve Months -2.31
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 21.7608
Fifty Day Average Change 2.2792015
Fifty Day Average Change Percent 0.10473887
Fifty Two Week Change Percent 21.169353
Fifty Two Week High 28.38
Fifty Two Week High Change -4.3399982
Fifty Two Week High Change Percent -0.15292454
Fifty Two Week Low 14.85
Fifty Two Week Low Change 9.190001
Fifty Two Week Low Change Percent 0.61885524
Fifty Two Week Range 14.85 - 28.38
Financial Currency USD
First Trade Date Milliseconds 1,777,642,200,000
Float Shares 18,434,316
Forward Eps -2.57328
Forward P E -9.342162
Full Exchange Name NasdaqGS
Full Time Employees 58
Fullday Change -2.21
Fullday Change Percent -8.41904
Fullday Price 24.04
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.35081002
Held Percent Institutions 0.70595
Implied Shares Outstanding 53,530,550
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-05-01
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Long Name Seaport Therapeutics, Inc.
Market us_market
Market Cap 1,286,874,496
Market State CLOSED
Max Age 86,400
Message Board Id finmb_1877598160
Most Recent Quarter 1,782,777,600
Net Income To Common -134,687,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,401,965,104
Number Of Analyst Opinions 6
Open 26.2
Operating Cashflow -88,725,000
Operating Margins 0.0
Payout Ratio 0.0
Phone (617) 807-4062
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 24.04
Post Market Time 1,787,959,806
Previous Close 26.25
Price Eps Current Year -4.07439
Price Hint 2
Price To Book -0.53963053
Profit Margins 0.0
Quick Ratio 17.747
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.42857
Region US
Regular Market Change -2.21
Regular Market Change Percent -8.41904
Regular Market Day High 26.865
Regular Market Day Low 24.04
Regular Market Day Range 24.04 - 26.865
Regular Market Open 26.2
Regular Market Previous Close 26.25
Regular Market Price 24.04
Regular Market Time 1,787,947,200
Regular Market Volume 144,826
Sand P52 Week Change 0.20204377
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 53,530,550
Shares Percent Shares Out 0.0563
Shares Short 3,012,877
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 1,980,276
Short Name Seaport Therapeutics, Inc.
Short Percent Of Float 0.0592
Short Ratio 27.05
Source Interval 15
State MA
Symbol SPTX
Target High Price 50.0
Target Low Price 30.0
Target Mean Price 37.0
Target Median Price 35.0
Total Cash 273,308,992
Total Cash Per Share 5.106
Total Debt 5,016,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.31
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 19.878313
Two Hundred Day Average Change 4.161688
Two Hundred Day Average Change Percent 0.2093582
Type Disp Equity
Volume 144,826
Website https://www.seaporttx.com
Zip 02,210-2186